The Thousand-people Assembly of
Pharmaceuticals Industry


BIOLIGN Conference Suzhou 2024



Embarking on a New Journey towards Innovation
for Future Pharmaceuticals

April 16-17 | Suzhou, China

BIOLIGN CONFERENCE

The BIOLIGN Conference Suzhou 2024 is dedicated to providing a high-level communication and exhibition platform for local/international pharmaceutical companies, Biotech firms, CRO/CDMO/ CMO, investment institutions, synthetic biology technology companies, single-cell and multiomics research institutions, instrument/equipment/reagent suppliers, technology/software/ service providers, law firms/consulting agencies, as well as parks, governments, research institutes, and universities. Leaders in the innovation ecosystem will gather at the conference to condense opinions, refine consensus and gain insights into cutting-edge trends and technological innovations in the pharmaceutical industry, which is to explore an innovative progress path to industrial cooperation of biomedicine.

Click here for post-event highlights and live coverage of BIOLIGN Thousand-people Assembly 2023 in Suzhou!

Download Post-event Report of East China Conference

BIOLIGN 2024@Suzhou

2500+

ATTENDEES

150+

SPEAKERS

350+

B2B MATCHMAKING

80+

SPONSORS

Embarking on a New Journey towards
Innovation for Future Pharmaceuticals

Part of Previous Speakers

Dawei Ma

Academician
The Chinese Academy of
Sciences
 
 

Hongzhou Lu

AAM Fellow
Dean of The Third People's
Hospital of Shenzhen
 

Xumu Zhang

RAE Foreign Member
 
 
 
 

Jens Ewert

Life Sciences &
Health Care Leader
Deloitte China
 
 

Jinhui Li

General Manager of
Hospital's Emergency BU
Pfizer China
 
 

Kaisheng Huang

CQO
RemeGen Co., Ltd.

 
 

Judy Deng

Head of Market Access and
Key Account Department
Novartis China
 
 

Hongwei Xie

VP
Innovent Biologics

 
 

Ning Yuan

VP & Co-CBO
FosunPharma
 
 
 

Li Mao

VP, GM of Research and
Development&CMO
SciClone
 
 

Mingxiu Hu

SVP
Akeso
 
 
 

Li Chen

Founder and
CEO,CSO
Hua Medicine
 
 

Shaojing Hu

Chairman&CEO
3H Pharmaceuticals
 
 
 

Bo Shan

CSO
Antengene
 
 
 

Dongzhou Liu

CSO & President of
Global Development
Huadong Medicine
 
 

Cheng Zhang

SVP & CSO
Gmax Biopharm LLC
 
 
 

Aimin Hui

General Manager
SharpSight Biopharma
Consulting
 
 

Wenzhi Tian

Chairman and GM
ImmuneOnco
 
 
 

Limo Chen

CSO VP of Drug Discovery
of Biopharmaceuticals
HEC Group
 
 

Li Zhou

CSO
Juventas Cell
Therapy
 
 

Gang Qin

CEO/Founder/Chairman
GeneQuantum
Healthcare
 
 

Ruhong Jiang

CEO
ASC Therapeutics
 
 
 

Gong Chen

Founder
NeuExcell
NeuExcell
Therapeutics
 

Fubing Li

Co-Founder/CSO
Constimulus
 
 
 

Wenji Dong

Founder&CEO
Genmedicn Biopharma
 
 
 

Jiaqiang Cai

Co-founder&CSO&CSO
MediLink Therapeutics
 
 
 

Wenjun Zhang

CEO
ExcelMab
 
 
 

Penghui Zhou

创始人
Founder
Fanen Biotechnology
 
 

Dan Liu

Senior Partner
CDH Investments
 
 
 

Bo Liu

Managing Director
CDIB Capital
 
 
 

Xiaoxia Zhang

VP, Global Listing Services
HKEX
 
 
 

Hong Wen

Partner
Shanghai Biomedical
Industry Equity Investment Fund
 
 

Jianhua Su

SVP &
General Manager
EpimAb
 
 

Jiong Lan

Founder&CEO
GenFleet Therapeutics
 
 
 

Ke Wu

CEO
BravoVax
 
 
 

Eric Koo

CEO
Overland ADCT BioPharma
 
 
 

Shan Gao

SVP
Suzhou Ribo
 
 
 

Hugh Davis

COO&President of
U.S. Branch
Biosion
 
 

Tony Guo

VP and Global Head of
Statistics and Data Sceince
BeiGene
 
 

Qiusong Tang

Head, Roche China
Accelartor
Roche
 
 

Ling Yang

VP
CTTQ PHARMA
 
 
 

Hui Feng

Managing Director
&COO
Junshi Biosciences
 
 

James Yan

Chief Operating Officer, R&D
Zai Lab Limited
 
 
 

Wei Long

Executive VP
of Preclinical R&D
JACOBIO
 
 

Weimin Tang

EVP
I-Mab Biopharma
 
 
 

Liandong Ma

VP/ Head of Institute of R&D
Kintor Pharmaceutical Limited
 
 
 

Jin Han

General Manager
Tasly Pharmaceutical
 
 
 

Hena Shi

VP & GM of Oncology Division
Betta Pharmaceuticals
 
 
 
In Alphabetical Order
Job Titles Align with the Newest Information

Part of Media Partners

Industry Insights – Empowering Innovations



Selected Product & Technical White Papers



Selected Research Report from Consultancies



Exclusive Interviews of Executives and Experts

Spectacle of Previous Conferences

Formats of BIOLIGN 2024